AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01287260
Drug: Nifedipine (Adalat, BAYA1040)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAYA1040_Nifedipine 40mg once daily (OD)
Trial: NCT01343329
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
Trial: NCT01343329
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
Trial: NCT01853319
Drug: Regorafenib (Stivarga, BAY73- 4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Trial: NCT05195242
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ATC code H02AB02
Trial: NCT02687724
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
Trial: NCT00100282
Drug: PPI-1019 (APAN)
RxNorm normalized name: PPI-1019
DrugBank: PPI-1019 (DB05832)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02159872
Drug: Omacetaxine
RxNorm normalized name: omacetaxine
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
Trial: NCT02852239
Drug: dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose dabrafenib 100 mg
Trial: NCT02140268
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
Trial: NCT02140268
Drug: AZD1722 and Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
Trial: NCT00288431
Drug: ridaforolimus
RxNorm normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
Trial: NCT02839213
Drug: Hyoscine Butyl bromide
RxNorm normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03604783
Drug: TP-1287
RxNorm normalized name: TP-1287
DrugBank: TP-1287 (DB18104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-1287 by oral administration
Trial: NCT02839213
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01156129
Drug: stool softener
RxNorm normalized name: STOOL SOFTENER
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ducosate sodium, Milk of Magnesia, dulcolax
Trial: NCT01061073
Drug: Omexel
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02436993
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
Trial: NCT02436993
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
Trial: NCT02436993
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
Trial: NCT02436993
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
Trial: NCT02436993
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
Trial: NCT03783312
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Trial: NCT00001360
Drug: 0-15 Water
RxNorm normalized name: water, O-15
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04215731
Drug: Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
Trial: NCT01114191
Drug: ABT-869
RxNorm normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
Trial: NCT01114191
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg days 6-11
Trial: NCT03012503
Drug: BioFreeze
RxNorm normalized name: Biofreeze
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
Trial: NCT04062097
Drug: Dabigatran Etexilate Oral Capsule [Pradaxa]
RxNorm normalized name: dabigatran etexilate Oral Capsule [Pradaxa]
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
Trial: NCT04062097
Drug: Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]
RxNorm normalized name: Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
Trial: NCT02938299
Drug: L19IL2 + L19TNF
RxNorm normalized name: L19IL2
DrugBank: Darleukin (DB17157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of L19IL2 and L19TNF once weekly
Trial: NCT00905164
Drug: Topiramate Capsules, 25 mg
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate Capsules, 2 x 25 mg
Trial: NCT02875743
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01582477
Drug: EXPAREL 20 mL
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EXPAREL 266 mg (undiluted)
Trial: NCT01582477
Drug: EXPAREL 40 mL
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
Trial: NCT01615939
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.625% with epinephrine 1:300,000
Trial: NCT01615939
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
Trial: NCT04396756
Drug: PLN-74809
RxNorm normalized name: PLN-74809
DrugBank: PLN-74809 (DB16515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLN-74809
Trial: NCT00091949
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a thiazolidinedione drug
Trial: NCT00269217
Drug: Comparator: niacin (+) laropiprant
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment 12 Weeks
Trial: NCT02647619
Drug: Xiapex
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of collagenase of primary dupytren cord
Trial: NCT01183806
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
Trial: NCT01105481
Drug: Amisulpride add-on
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
Trial: NCT01084655
Drug: TAK-700
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Trial: NCT01084655
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Trial: NCT01084655
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Trial: NCT03808298
Drug: Balovaptan therapeutic dose Treatment A
RxNorm normalized name: Moisturel Therapeutic
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
Trial: NCT04530617
Drug: Camostat Mesilate
RxNorm normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04530617
Drug: Artemisia Annua Leaf
RxNorm normalized name: ARTEMISIA ANNUA LEAF
DrugBank: Artemisia annua leaf (DB16597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea bags
Trial: NCT03347721
Drug: lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% lidocaine jelly, injected into the urethra
Trial: NCT03808298
Drug: Balovaptan supra-therapeutic dose Treatment B
RxNorm normalized name: Supra Sulfa
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
Trial: NCT03808298
Drug: Active control [moxifloxacin] on Day 2 Treatment C
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.
Trial: NCT03808298
Drug: Placebo for Balovaptan Treatment D
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-14: Matching placebo for balovaptan for 14 days.
Trial: NCT03808298
Drug: Placebo for Moxifloxacin Treatment A
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Trial: NCT03808298
Drug: Placebo for Moxifloxacin Treatment B
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
Trial: NCT03808298
Drug: Moxifloxacin Treatment C
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.
Trial: NCT03808298
Drug: Placebo for Moxifloxacin Treatment C
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Trial: NCT03808298
Drug: Placebo for Moxifloxacin Treatment D
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
Trial: NCT01921582
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies).
Trial: NCT03666663
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal application using the Sphenocath device- cleared by FDA
Trial: NCT03666663
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal application using the Sphenocath device- cleared by FDA
Trial: NCT03666663
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal application using the Sphenocath device- cleared by FDA
Trial: NCT03780673
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 400/8 hours for 12 months
Trial: NCT03780673
Drug: Placebo of Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of Rifaximin/8 hours for 12 months
Trial: NCT00535496
Drug: sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Trial: NCT01841099
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine granules
Trial: NCT01704716
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given during Rapid COJEC and modified N7 therapy
Trial: NCT01704716
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
Trial: NCT01704716
Drug: ch14.18/CHO
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ch14.18/CHO antibody is given during MRD treatment
Trial: NCT01704716
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
Trial: NCT01441882
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01704716
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide is given during Induction Treatment (both R3 randomisation arms)
Trial: NCT01704716
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is given during Induction Treatment (both R3 randomisation arms)
Trial: NCT01704716
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF is given during Induction Treatment
Trial: NCT01704716
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
Trial: NCT01704716
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan is given during MAT treatment
Trial: NCT03925285
Drug: Bevacizumab-800CW
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
Trial: NCT00000817
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg oral tablet taken daily
Trial: NCT00000817
Drug: Amitriptyline hydrochloride placebo
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet taken daily
Trial: NCT03428984
Drug: EXPAREL
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EXAPREL 266 mg in 20 mL
Trial: NCT02141295
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be administered according to dose and schedule described in respective arm.
Trial: NCT02141295
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered according to dose and schedule described in respective arm.
Trial: NCT02141295
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid will be administered according to dose and schedule described in respective arm.
Trial: NCT02141295
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered according to dose and schedule described in respective arm.
Trial: NCT02141295
Drug: Vanucizumab
RxNorm normalized name: Vanucizumab
DrugBank: Vanucizumab (DB12317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanucizumab will be administered according to dose and schedule described in respective arm.
Trial: NCT00551811
Drug: SB-656933-AAA
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
Trial: NCT01710501
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grazoprevir tablet, orally, once per day at assigned dose
Trial: NCT01710501
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
Trial: NCT00628667
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg orally twice daily
Trial: NCT04003467
Drug: EBP05
RxNorm normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01696110
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
Trial: NCT01696110
Drug: heparin plus tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combined use of heparin and tirofiban during PCI